ArticleMolecular and cellular biochemistry2018
miR-124 promotes proliferation and neural differentiation of neural stem cells through targeting DACT1 and activating Wnt/β-catenin pathways.
Article in Molecular and cellular biochemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 54 citations in OpenAlex.
- [MiR-124 ameliorates MK-801-induced anxiety-like behaviors in mice by promoting hippocampal neural stem cell proliferation and differentiation].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- MicroRNA and Alzheimer's disease: Diagnostic biomarkers and potential therapeutic targets.Neural regeneration research · 2026Article
- Unravelling the Road to Recovery: Mechanisms of Wnt Signalling in Spinal Cord Injury.Molecular neurobiology · 2024Review
- 3D printing of interferon γ-preconditioned NSC-derived exosomes/collagen/chitosan biological scaffolds for neurological recovery after TBI.Bioactive materials · 2024Article
- miR-124-3p regulates the proliferation and differentiation of retinal progenitor cells through SEPT10.Cell and tissue research · 2023Article
- MicroRNA‑124: an emerging therapeutic target in central nervous system disorders.Experimental brain research · 2023Review
- The factors affecting neurogenesis after stroke and the role of acupuncture.Frontiers in neurology · 2023Review
- Review
- miR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases.Cellular and molecular neurobiology · 2022Review
- Sevoflurane induces microRNA-18a to delay rat neurodevelopment via suppression of the RUNX1/Wnt/β-catenin axis.Cell death discovery · 2022Article
- The role of Wnt/mTOR signaling in spinal cord injury.Journal of clinical orthopaedics and trauma · 2022Review
- The Role of DACT Family Members in Tumorigenesis and Tumor Progression.International journal of biological sciences · 2022Review
- MicroRNA-218 aggravates HExperimental and therapeutic medicine · 2021Article
- MiR-124 and Small Molecules Synergistically Regulate the Generation of Neuronal Cells from Rat Cortical Reactive Astrocytes.Molecular neurobiology · 2021Article
- RVG29-modified microRNA-loaded nanoparticles improve ischemic brain injury by nasal delivery.Drug delivery · 2020Article
- Differential expression of microRNAs in the human fetal left and right cerebral cortex.Molecular biology reports · 2020Article
- Role of miR-124 in the regulation of retinoic acid-induced Neuro-2A cell differentiation.Neural regeneration research · 2020Article
- Differential miRNA Expression: Signature for Glaucoma in Pseudoexfoliation.Clinical ophthalmology (Auckland, N.Z.) · 2020Article
- Toxicity mechanism of sevoflurane in neural stem cells of rats through DNA methylation.Experimental and therapeutic medicine · 2019Article
- Downregulation of an Evolutionary Young miR-1290 in an iPSC-Derived Neural Stem Cell Model of Autism Spectrum Disorder.Stem cells international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Neural stem cells (NSCs) are multipotent and undifferentiated cells with the potential to differentiate into neuronal lineages and gliocytes. NSCs have the ability to generate and regenerate the brain, indicating the possibility of cell-based therapies for neurological disorders. miR-124 has been demonstrated as a modulator in the survival, expansion, and differentiation of NSCs. However, the underlying molecular mechanisms of miR-124 in NSC development are still far from being understood. The expressions of miR-124, dishevelled binding antagonist of beta-catenin 1 (DACT1), ki-67, Nestin, β-tubulin III, glial fibrillary acidic protein (GFAP), β-catenin, cyclinD1, and glycogen synthase kinase-3β (GSK-3β) were examined by qRT-PCR or western blot. Bioinformatics and Dual-Luciferase reporter assay were used to identify the interaction between miR-124 and DACT1. MTS analysis was performed to measure the viability of NSCs. Enhanced expression of miR-124 and lowered expression of DACT1 were observed during a 14-day NSC differentiation period. DACT1 was verified as a direct target of miR-124. Moreover, overexpression of miR-124 promoted NSC proliferation and induced neuron-specific differentiation, presented as increased cell viability, higher neurosphere number, elevated ki-67, Nestin, β-tubulin III expressions, and decreased GFAP expression. Similarly, DACT1 downregulation facilitated proliferation and neuronal differentiation of NSCs. Furthermore, DACT1 overexpression impaired miR-124-induced proliferation and differentiation of NSCs. Additionally, miR-124 stimulated Wnt/β-catenin signaling via suppressing DACT1 expression. miR-124 promoted proliferation and induced NSC differentiation to neurons by activation of Wnt/β-catenin pathway via targeting DACT1, providing a potential target and aiding the development of cell-based therapies for neurological disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.